PILL
PILL 2-star rating from Upturn Advisory

Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL)

Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL) 2-star rating from Upturn Advisory
$12.43
Last Close (24-hour delay)
Profit since last BUY49.04%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 52 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: PILL (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 2 star rating for performance

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type ETF
Historic Profit 107.05%
Avg. Invested days 51
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
ETF Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Volume (30-day avg) -
Beta 1.79
52 Weeks Range 3.60 - 10.53
Updated Date 06/29/2025
52 Weeks Range 3.60 - 10.53
Updated Date 06/29/2025

About Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF

Exchange NYSE ARCA
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

The fund invests at least 80% of its net assets in financial instruments, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is a modified equal-weighted index that is designed to measure performance of the stocks, defined as pharmaceutical and medical stocks, comprising the S&P Total Market Index that are classified in the GICS pharmaceuticals sub-industry. The fund is non-diversified.